Medical Oncology

Dermatology

Questions discussed in this category

How do you manage patients with chemotherapy-induced paronychia?

How would you manage a patient with essential thrombocythemia and persistent pruritus despite adequate control of CBC with hydroxyurea and aspirin?

ET is JAK2+

1 Answer available

How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?

Do you have a preferred sequence of therapies for diffuse skin limited MF?

1 Answer available

Would you still consider durvalumab consolidation after definitive chemoradiation for patients with Stage III NSCLC who are on stable weekly methotrexate dosing for psoriasis/psoriatic arthritis?

1 Answer available

How would you manage a nodal recurrence of cutaneous SCC if the patient is unable to receive surgery for 6-8 weeks?

In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...

1 Answer available

How would you approach an early inguinal recurrence after surgical resection of Merkel Cell carcinoma in the popliteal region?

2 Answers available

Is there a role for adjuvant systemic therapy (in addition to adjuvant radiation) in an early-stage, resected cutaneous angiosarcoma of the head/neck?

Post-auricular cutaneous angiosarcoma, pT1 (19 mm) with negative margins. Unclear if there is any indication for systemic therapy, given early stage a...

1 Answer available

What type of surveillance would you recommend following resection of primary mucinous carcinoma of the skin?

1 Answer available

Would you continue cemiplimab or pembrolizumab following resection of initially unresectable cutaneous squamous cell carcinoma?

What if pathology showed NED?

3 Answers available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

Is there benefit in switching between sonedegib to vismodegib or vice versa for patients with unresectable basal cell carcinoma of the face that progresses on first line hedgehog inhibitor?

1 Answer available

Would you avoid the use of a TNF inhibitors in patients with a remote history of melanoma, including those with ocular melanoma?

1 Answer available